Herbert Irving Comprehensive Cancer Center
Matthew Ingham, MD
Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow.

Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] A study for patients with AML, MDS, Myelofibrosis or solid tumors using study drug INCB059872
Cancer [ CLOSED ] A study for patients with advanced solid tumors or lymphomas using study drug MK-1454
Gastrointestinal [ CLOSED ] INVICTUS Study of Drug in Advanced Gastrointestinal Stromal Tumors
Cancer [ CLOSED ] Study of Drug (MK-2118) in Patients with Solid Tumors or Lymphomas
Cancer [ CLOSED ] Study of MIW815 (ADU-S100) in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Sarcoma [ CLOSED ] A Study of AL3818 (Anlotinib) in Patients with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Sarcoma [ CLOSED ] A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Sarcoma [ CLOSED ] Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Sarcoma [ CLOSED ] Study of Talimogene Laherparepvec (T-VEC) and Radiation in Soft Tissue Sarcoma
Cancer [ CLOSED ] Genetic Analysis of Blood and Tissue Samples From Participants With Advanced Cancer
Cancer [ CLOSED ] Study of Intratumorally Administered INT230-6 in Adult Subjects with Solid Tumors
Sarcoma [ CLOSED ] Tazemetostat in Combination With Doxorubicin as Therapy for Advanced Epithelioid Sarcoma
Cancer [ CLOSED ] Study Evaluating BI 1387446 Alone and in Combination with BI 754091 in Solid Tumors
Cancer [ CLOSED ] A First-in-Human Study of CDK-002 (exoSTING) in Subjects with Advanced/Metastatic Solid Tumors
Cancer [ CLOSED ] A Study of ASP9801 in Patients With Advanced Metastatic Solid Tumors
Cancer [ CLOSED ] Study of GSK3901961 and GSK3845097 in Patients with Synovial Sarcoma or Non-Small Cell Lung Cancer (NSCLC)